Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Apr 30, 2019
Appendix 4C - quarterly
Apr 29, 2019
Notice of Annual General Meeting/Proxy Form
Apr 26, 2019
Appendix 4G
Apr 26, 2019
Annual Report to shareholders
Apr 26, 2019
Update on development plan for NNZ-2591
Mar 28, 2019
Neuren's Rett syndrome Phase 2 trial published in Neurology
Feb 27, 2019
Fundamentals strong as Neuren advances neuroscience pipeline
Feb 27, 2019
Preliminary Final Report and statutory accounts
Feb 18, 2019
NNZ-2591 positive effects in Phelan-McDermid syndrome model
Feb 04, 2019
Plans for Phase 3 trial in Rett syndrome
Previous
1
2
3
4
Next
